NEW YORK, Dec. 13 — Pharsight and Roche Bioscience will collaborate to link Roche’s genomics discovery program with Pharsight’s software, modeling, and simulation technologies for clinical drug development, the companies said Thursday. The partnership is intended to apply genetic analysis to clinical trials and drug development in order to spur research into individually tailored drugs.
By the terms of the agreement, Pharsight will develop models that relate drug treatment to human genetic differences and clinical outcomes. The company will use data from Roche’s mouse genomics discovery platform to identify traits relating to drug efficacy. Pharsight will use its clinical trial simulation software to explore trial design and assess how best to incorporate genetic analysis into trial design, and Roche will identify and test the optimal design.
Financial terms of the agreement were not disclosed.
Genomic research can improve efficiency in clinical development as well as drug discovery, said Gary Peltz, head of genetics for the Roche Bioscience Inflammatory and Viral Disease Unit, in a statement. The Pharsight collaboration will help Roche “link a genomics discovery platform to the clinical development of new drugs.”
“We expect to have a quantitative demonstration of the general benefits of exploiting genetic knowledge in clinical trials,” said Pharsight founder Greg Lee in a statement. “If the technology is successful at optimizing clinical trial design, then the same principles should apply to optimizing drug treatment for patients.”
Roche Bioscience, located in Palo Alto, Calif., is one of five Roche Group research centers.Pharsight, based in Mountain View, Calif., uses computer drug/disease models, clinical trial simulation, and dynamic market models to help companies in drug development and commercialization.